Identify Undiagnosed Lung Cancer Risk in Your Population

OptiStrata™ software identifies Medicare Advantage plan members with the greatest risk of currently undiagnosed, asymptomatic lung cancer.

Earlier detection results in earlier treatment, improved patient outcomes, and lower costs for payers and value-based providers.

Why We Focus On Lung Cancer

Lung and bronchial cancer accounts for over 225,000 new diagnoses in the US each year, with approximately 73% of patients diagnosed at late stages (III or IV).

Earlier detection leads to a significant reduction in costs versus late-stage diagnosis and treatments, generally exceeding $100,000 per patient in the first year after diagnosis.

Lung cancer has an overall 5-year relative survival rate of 27% meaning roughly 3 in 4 people do not live longer than 5 years once diagnosed.

However, for the 27% of patients who are diagnosed at an early, localized stage, the 5-year survival rate significantly improves to 64%.

Our Opportunity

Cancer is the leading cause of death across the globe. And, it’s growing:

2024 will be the first year that new cancer diagnoses exceed 2M in the U.S.1

Annual global cancer diagnoses are expected to rise to 29.9M by 2040.2

U.S. cancer expenditures were $208.9B in 2020 and are trending up as the U.S. population ages.3

Our Mission

Together, We Can Lower Healthcare Costs and Improve Patient Outcomes.

Treating metastatic cancers can lead to 7 times higher costs than treating early-stage cancers.4

Early diagnosis across 19 cancers could result in an estimated $26 billion cost-savings, representing about 17% of the direct costs related to cancer treatment.5

“The greatest need we have today in the human cancer problem, except for a universal cure, is a method of detecting the presence of cancer before there are any clinical signs of symptoms.”
– Sidney Farber, letter to Etta Rosensohn, November 1962

Schedule a Demo

Fill out the form below and we will be in touch.